Estimulación ovárica en reproducción asistida

Luis Ernesto Escudero Velando

doi:10.31403/rpgo.v58i71

Authors

Luis Ernesto Escudero Velando Director Medico Grupo PRANOR de Reproducción Asistida.

DOI:

https://doi.org/10.31403/rpgo.v58i71

Abstract

In recent times, there have been many protocols developed for ovulation induction in IVF, with the main objective of getting more oocytes in the same cycle without premature luteinization. Nowadays there is a wide variety of medications used for this purpose that have made IVF easier and more successful. In this chapter we try to introduce some of these ovulation induction protocols as well as some alternatives.

Downloads

Download data is not yet available.

References

Jones HW, Jones GS, Andrews MC, Acosta A, Bundren C, et al. The program for in vitro fertilization at Norfolk. Fertil Steril. 1982;38(1):14-21.

Bellver J, Busso C, Pellicer A, Remohí J, Simón C. Obesity and assisted reproductive technology outcomes. Reprod Biomed Online. 2006;12(5):562-8.

Bellver J, Martínez-Conejero JA, Labarta E, Alamá P, Melo MA, Remohí J, Pellicer A, Horcajadas JA. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. Fertil Steril. 2011;95(7):2335-41.

Gysler M, March CM, Mishell DR Jr, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril. 1982;37(2):161-7.

Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002;77(1):91-7.

Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83(7):2361-5.

Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ. 1988;297(6655):1024-6.

Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with inadequate response to clomiphene citrate. Fertil Steril 2011;75:305-9.

Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006;85:277-84

Bagratee JS, Lockwood G, Lópz-Bernal A, Barlow DH, Ledger WL. Comparison of highly purified FSH (metrodinhigh purity) with pergonal for IVF superovulation. J Assist Reprod Genet. 1998;15(2):65-9.

Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Fertini F, Perri T, Parmegiani L. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertil Steril. 2003;80(2):390-7.

Bellver J, Escudero E, Pellicer A. Ovarian mutilating surgery is not an option in the management of severe ovarian hyperstimulation syndrome (OHSS). Hum Reprod. 2003;18(7):1363-7. DEBATE–continued. Sobre el artículo: Amarin ZO. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS). An aggressive, but perhaps life-saving procedure. Hum Reprod. 2203;18:1-6.

Westergaard LG, Erb K, Laursen S, Rasmussen PE, Rex S. The effect of human menopausal gonadotrophin and highly purified urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down regulated women. Human Reprod. 1996;11(6):1209-13.

Many A, Azem F, Lessing JB; Yovel I, Yavetz H, Amit A. Pregnancy rate in IVF rescue in high responders to human menopausal gonadotropin. J Assist Reprod Genet. 1999;16(10): 520-2.

Brinsden P, Akagbosu F, Gibbons LM, Lancaster S, Gourdon D, Engrand P, Loumaye E. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2000;73(1):114-6

Harlin J, Csemiczky G, Wramsby H, Fried G. Recombinant follicle stimulating hormone in in vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Hum Reprod. 2000;15(2): 239-44.

Jennings JC, Moreland K, Peterson CM. In vitro fertilization: A review of drug therapy and clinical management. Drugs. 1996;52(3):313-43.

Edelstein MC, Seltman HJ, Cox BJ, Robinson SM, Shaw RA, Muasher SJ. Progesterone levels on day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome. Fertil Steril. 1990;54(5):853-7.

Silverberg KM, Burns WN, Olive DL, Riehl RM, Schenken RS. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. J Clin Endocrinol Metab. 1991;73(4):797-803.

Ubaldi F, Albano C, Peukert M, Riethmuller-Winzen H, Smitz J, Van Steirteghem A, Devroey P. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles. Hum Reprod. 1996;11(7):1405-7.

Bosch E, Valencia I, Escudero E, Crespo J, Simón C, Remohí J, Pellicer A. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80(6):1444-9.

Ubaldi F, Smitz J, Bourgain C, Van Steirteghem A, Devroey P. Pregnancy and birth after high serum progesterone concentrations during follicular phase in an in-vitro fertilization cycle with gonadotrophin-releasing hormone agonist suppression. Hum Reprod. 1995;10(1):211-3.

Olivennes F, Freedman R. Friendly IVF: the way of the future? Hum Reprod 1998;13:1121-4.

Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM, Bouchard P. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil Steril. 1991; 56: 923-7.

Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279-90.

Ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH antagonist ganirelix to prevent premature LH surges in women undergoing controlled ovarian stimulation with recombinant FSH. Human Reprod 1998;13:3023-31.

Escudero E, Bosch E, Crespo J, Simón C, Remohí J, Pellicer A. Comparison of two different multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertil Steril. 2004;81(3):562-6.